Back to Results
First PageMeta Content
Pharmacology / Unique Device Identification / Dermatologic and Ophthalmic Drugs Advisory Committee / Food and Drug Administration / Pharmaceutical sciences / Clinical research


Federal Register / Vol. 79, No[removed]Friday, November 21, [removed]Notices Reduction Act of[removed]U.S.C. 3501– [removed]The collections of information in 21 CFR[removed]and Form FDA 356h have been approved under OMB con
Add to Reading List

Document Date: 2014-11-21 08:51:04

Open Document

File Size: 205,90 KB

Share Result on Facebook

City

Washington / DC / /

Company

Special Medical Programs / Adobe / Astellas Pharma Global Development Inc. / /

/

Facility

University of Virginia / White Oak Campus / Registration The FDA Conference Center / FDA White Oak Campus / /

/

IndustryTerm

diagnostic and therapeutic products / throughput technologies / transportation / pharmaceutical industry / pharmaceutical and diagnostic industries / therapeutic products / /

MedicalCondition

invasive aspergillosis / tumor / disease / mucormycosis / /

Organization

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration / Accreditation Commission for Education / Center for Translational and Regulatory Sciences / University of Virginia / American Nurses Credentialing Center / Food and Drug Administration / Division of Dockets Management / FDA / Public Workshop DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY / Anti-Infective Drugs Advisory Committee / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH AND HUMAN SERVICES / Meeting AGENCY / /

Person

Silver Spring / Jill Hartzler Warner / Leslie Kux / /

Position

Governor / Associate Commissioner / Associate Commissioner for Policy / /

ProvinceOrState

Virginia / Maryland / /

Technology

high throughput technologies / diagnostic tests / http / drug development / /

URL

www.fda.gov/AboutFDA / http /

SocialTag